ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis
USA - NASDAQ:ADMA - US0008991046 - Common Stock
17.18 USD
+0.82 (+5.01%)
17.18 USD
0 (0%)
Taking everything into account, ADMA scores 6 out of 10 in our fundamental rating. ADMA was compared to 533 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, ADMA could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
ADMA had positive earnings in the past year.
In the past year ADMA had a positive cash flow from operations.
In the past 5 years ADMA reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of 37.42%, ADMA belongs to the top of the industry, outperforming 98.87% of the companies in the same industry.
ADMA's Return On Equity of 52.45% is amongst the best of the industry. ADMA outperforms 98.50% of its industry peers.
ADMA has a Return On Invested Capital of 25.43%. This is amongst the best in the industry. ADMA outperforms 98.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROIC | 25.43% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ADMA (44.06%) is better than 98.31% of its industry peers.
ADMA's Operating Margin of 32.82% is amongst the best of the industry. ADMA outperforms 97.00% of its industry peers.
ADMA has a better Gross Margin (53.00%) than 75.98% of its industry peers.
ADMA's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
ADMA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ADMA has been increased compared to 5 years ago.
The debt/assets ratio for ADMA has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 16.48 indicates that ADMA is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 16.48, ADMA belongs to the best of the industry, outperforming 88.74% of the companies in the same industry.
ADMA has a debt to FCF ratio of 1.12. This is a very positive value and a sign of high solvency as it would only need 1.12 years to pay back of all of its debts.
ADMA has a better Debt to FCF ratio (1.12) than 93.62% of its industry peers.
A Debt/Equity ratio of 0.18 indicates that ADMA is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.18, ADMA is not doing good in the industry: 66.60% of the companies in the same industry are doing better.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Altman-Z | 16.48 |
ROIC/WACC2.91
WACC8.73%
2.3 Liquidity
ADMA has a Current Ratio of 5.33. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.33, ADMA perfoms like the industry average, outperforming 58.35% of the companies in the same industry.
A Quick Ratio of 2.78 indicates that ADMA has no problem at all paying its short term obligations.
ADMA has a worse Quick ratio (2.78) than 63.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 92.86% over the past year.
The Revenue has grown by 65.15% in the past year. This is a very strong growth!
Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 70.84% on average per year.
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)65.15%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.01% yearly.
The Revenue is expected to grow by 20.94% on average over the next years. This is a very strong growth
EPS Next Y21.04%
EPS Next 2Y37.55%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.53%
Revenue Next 5Y20.94%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ADMA is valuated quite expensively with a Price/Earnings ratio of 31.81.
ADMA's Price/Earnings ratio is rather cheap when compared to the industry. ADMA is cheaper than 92.12% of the companies in the same industry.
ADMA is valuated rather expensively when we compare the Price/Earnings ratio to 25.45, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 18.16, which indicates a rather expensive current valuation of ADMA.
93.81% of the companies in the same industry are more expensive than ADMA, based on the Price/Forward Earnings ratio.
ADMA's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 34.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.81 | ||
| Fwd PE | 18.16 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 92.87% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaply inside the industry as 92.12% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 62.48 | ||
| EV/EBITDA | 23.77 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ADMA may justify a higher PE ratio.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 35.80% in the coming years.
PEG (NY)1.51
PEG (5Y)N/A
EPS Next 2Y37.55%
EPS Next 3Y35.8%
5. Dividend
5.1 Amount
ADMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
17.18
+0.82 (+5.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners89.29%
Inst Owner Change5.87%
Ins Owners2.35%
Ins Owner Change-1.53%
Market Cap4.10B
Revenue(TTM)426.45M
Net Income(TTM)208.93M
Analysts84
Price Target27.8 (61.82%)
Short Float %7.27%
Short Ratio4.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.56%
Min EPS beat(2)-31.17%
Max EPS beat(2)-1.96%
EPS beat(4)1
Avg EPS beat(4)-7.13%
Min EPS beat(4)-31.17%
Max EPS beat(4)13.12%
EPS beat(8)4
Avg EPS beat(8)-13.7%
EPS beat(12)6
Avg EPS beat(12)-7.65%
EPS beat(16)9
Avg EPS beat(16)-4.75%
Revenue beat(2)0
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-2.51%
Revenue beat(4)2
Avg Revenue beat(4)1.84%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)10.99%
Revenue beat(8)6
Avg Revenue beat(8)4.93%
Revenue beat(12)10
Avg Revenue beat(12)6.13%
Revenue beat(16)14
Avg Revenue beat(16)6.66%
PT rev (1m)-6.23%
PT rev (3m)-6.23%
EPS NQ rev (1m)-2.17%
EPS NQ rev (3m)-10%
EPS NY rev (1m)4.7%
EPS NY rev (3m)-2.2%
Revenue NQ rev (1m)-0.51%
Revenue NQ rev (3m)0.17%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)-0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.81 | ||
| Fwd PE | 18.16 | ||
| P/S | 8.65 | ||
| P/FCF | 62.48 | ||
| P/OCF | 53.44 | ||
| P/B | 10.29 | ||
| P/tB | 10.4 | ||
| EV/EBITDA | 23.77 |
EPS(TTM)0.54
EY3.14%
EPS(NY)0.95
Fwd EY5.51%
FCF(TTM)0.27
FCFY1.6%
OCF(TTM)0.32
OCFY1.87%
SpS1.99
BVpS1.67
TBVpS1.65
PEG (NY)1.51
PEG (5Y)N/A
Graham Number4.5
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 37.42% | ||
| ROE | 52.45% | ||
| ROCE | 32.19% | ||
| ROIC | 25.43% | ||
| ROICexc | 31.27% | ||
| ROICexgc | 31.6% | ||
| OM | 32.82% | ||
| PM (TTM) | 44.06% | ||
| GM | 53% | ||
| FCFM | 13.84% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score5
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 1.12 | ||
| Debt/EBITDA | 0.45 | ||
| Cap/Depr | 140.25% | ||
| Cap/Sales | 2.34% | ||
| Interest Coverage | 13.21 | ||
| Cash Conversion | 46.9% | ||
| Profit Quality | 31.4% | ||
| Current Ratio | 5.33 | ||
| Quick Ratio | 2.78 | ||
| Altman-Z | 16.48 |
F-Score5
WACC8.73%
ROIC/WACC2.91
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y21.04%
EPS Next 2Y37.55%
EPS Next 3Y35.8%
EPS Next 5Y32.01%
Revenue 1Y (TTM)65.15%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year19.81%
Revenue Next 2Y22.86%
Revenue Next 3Y24.53%
Revenue Next 5Y20.94%
EBIT growth 1Y85.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.25%
EBIT Next 3Y41.34%
EBIT Next 5Y36.11%
FCF growth 1Y227.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y285.06%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 6 / 10 to ADMA.
Can you provide the valuation status for ADMA BIOLOGICS INC?
ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ADMA BIOLOGICS INC (ADMA) stock?
The Price/Earnings (PE) ratio for ADMA BIOLOGICS INC (ADMA) is 31.81 and the Price/Book (PB) ratio is 10.29.
Can you provide the financial health for ADMA stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 7 / 10.